Last reviewed · How we verify
Ad5-nCoV-IH
Ad5-nCoV-IH is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently FDA-approved. Also known as: aerosolized Ad5-nCoV, Convidecia.
Ad5-nCoV-IH is a bivalent recombinant COVID-19 vaccine delivered via inhalation, using an adenovirus type 5 vector. It is being studied as a potential booster for individuals who have previously received mRNA-based COVID-19 vaccines.
At a glance
| Generic name | Ad5-nCoV-IH |
|---|---|
| Also known as | aerosolized Ad5-nCoV, Convidecia |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (PHASE4)
- IH Convidecia as Second Booster Dose Against Breakthrough Infections (PHASE3)
- Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (PHASE3)
- A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes (NA)
- Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad5-nCoV-IH CI brief — competitive landscape report
- Ad5-nCoV-IH updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about Ad5-nCoV-IH
What is Ad5-nCoV-IH?
Who makes Ad5-nCoV-IH?
Is Ad5-nCoV-IH also known as anything else?
What development phase is Ad5-nCoV-IH in?
Related
- Manufacturer: Jiangsu Province Centers for Disease Control and Prevention — full pipeline
- Also known as: aerosolized Ad5-nCoV, Convidecia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing